Eli Lilly, Boehringer Ingelheim's Jardiance clinches heart failure edge with FDA nod for wider label

With one heart failure nod already in the books, Eli Lilly and Boehringer Ingelheim’s diabetes blockbuster Jardiance just racked up another key approval—opening the door to a much wider range of patients.

The U.S. FDA on Thursday blessed Lilly and Boehringer’s Jardiance with a label expansion to curb the risk of cardiovascular death and hospitalization in adults with heart failure. The move comes after the partners in November sent off an FDA application for the med to treat adults with heart failure independent of left ventricular ejection fraction.